- Home
- SAIA vs BMRN Comparison
SAIA vs BMRN Comparison
Compare SAIA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAIA | BMRN |
|---|---|---|
| Founded | 1924 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 10.0B |
| IPO Year | 2002 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SAIA | BMRN |
|---|---|---|
| Price | $337.06 | $59.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $349.53 | $89.74 |
| AVG Volume (30 Days) | 438.4K | ★ 2.9M |
| Earning Date | 02-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | ★ 10.58 | 2.68 |
| Revenue | ★ $3,233,286,000.00 | $3,094,001,000.00 |
| Revenue This Year | $2.33 | $13.35 |
| Revenue Next Year | $5.09 | $9.06 |
| P/E Ratio | $31.86 | ★ $22.18 |
| Revenue Growth | 1.96 | ★ 12.39 |
| 52 Week Low | $229.12 | $50.76 |
| 52 Week High | $538.03 | $73.51 |
Technical Indicators
Market Signals| Indicator | SAIA | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 60.46 |
| Support Level | $324.87 | $58.44 |
| Resistance Level | $334.40 | $60.58 |
| Average True Range (ATR) | 9.87 | 1.96 |
| MACD | -1.68 | 0.39 |
| Stochastic Oscillator | 60.77 | 64.63 |
Price Performance
Historical ComparisonAbout SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.